H19 is an imprinted long noncoding RNA abundantly expressed in embryonic liver and repressed after birth. We show that H19 serves as a lipid sensor by synergizing with the RNA-binding polypyrimidine tract-binding protein 1 (PTBP1) to modulate hepatic metabolic homeostasis. H19 RNA interacts with PTBP1 to facilitate its association with sterol regulatory element-binding protein 1c mRNA and protein, leading to increased stability and nuclear transcriptional activity. H19 and PTBP1 are up-regulated by fatty acids in hepatocytes and in diet-induced fatty liver, which further augments lipid accumulation. Ectopic expression of H19 induces steatosis and pushes the liver into a "pseudo-fed" state in response to fasting by promoting sterol regulatory element-binding protein 1c protein cleavage and nuclear translocation. Deletion of H19 or knockdown of PTBP1 abolishes high-fat and high-sucrose diet-induced steatosis. Conclusion: Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver. (HEPATOLOGY 2018;67:1768-1783 
H19 is an imprinted long noncoding RNA abundantly expressed in embryonic liver and repressed after birth. We show that H19 serves as a lipid sensor by synergizing with the RNA-binding polypyrimidine tract-binding protein 1 (PTBP1) to modulate hepatic metabolic homeostasis. H19 RNA interacts with PTBP1 to facilitate its association with sterol regulatory element-binding protein 1c mRNA and protein, leading to increased stability and nuclear transcriptional activity. H19 and PTBP1 are up-regulated by fatty acids in hepatocytes and in diet-induced fatty liver, which further augments lipid accumulation. Ectopic expression of H19 induces steatosis and pushes the liver into a "pseudo-fed" state in response to fasting by promoting sterol regulatory element-binding protein 1c protein cleavage and nuclear translocation. Deletion of H19 or knockdown of PTBP1 abolishes high-fat and high-sucrose diet-induced steatosis. Conclusion: Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver. (HEPATOLOGY 2018; 67:1768 -1783 N onalcoholic fatty liver disease, one of the most common causes of chronic liver disease, encompasses a histological spectrum of liver diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. (1, 2) Steatosis is defined as hepatic accumulation of triglyceride (TG) above 5% of liver weight and represents the hallmark of nonalcoholic fatty liver disease. (3) Beyond NASH, steatosis may progress to cirrhosis and ultimately hepatocellular carcinoma. (4) Increased TG deposition in the liver results from an imbalance of input, output, oxidation, and de novo synthesis of hepatic free fatty acids (FAs), (5, 6) which is controlled by genes in pathways of lipid uptake, secretion, oxidation, and synthesis. The induction of lipogenesis is mainly controlled by sterol regulatory element-binding protein 1c (SREBP1c), which is an endoplasmic reticulum membrane-bound protein that functions as a transcription factor in the liver. (7) In sterol-depleted cells, the membrane-bound
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precursor is cleaved to generate a soluble NH2-terminal fragment that translocates to the nucleus to activate the hepatic lipogenic program. Hyperactivation of SREBP1 causes TG accumulation and leads to hepatic steatosis. (8) Long noncoding RNAs (lncRNAs) are defined as transcripts that are above 200 nucleotides in length and without proof of protein coding potential. In the past decade, lncRNAs have come to the forefront of research interest in many fields. Recent studies have shown that lncRNAs are involved in the regulation of various cellular processes including lipid metabolism, microbial susceptibility, nuclear reprogramming, neural differentiation, and epigenetics. (9) (10) (11) Paternally imprinted and maternally expressed H19 is one of the first identified lncRNAs. The physiological and pathological effect of H19 on mRNA stability, tumor metastasis, and osteoblast differentiation have been reported. (12, 13) Of particular interest, expression of H19 RNA is high in fetal liver but diminishes significantly in adult liver. Intriguingly, such expression is up-regulated in human chronic liver diseases, (14) indicating an important regulatory role in hepatic function and metabolism.
Polypyrimidine tract-binding protein 1 (PTBP1, also known as PTB or hnRNP I) is an RNA binding protein that regulates mRNA stability and pre-mRNA splicing. (15) It also has been implicated in directing cell reprogramming (16) and brain tumor growth. (17) The finding that PTBP1 controls genes in insulin biosynthesis (18) suggests a potential function of PTBP1 in metabolic diseases.
In this study, we unravel an H19/PTBP1 metabolic circuit that dictates SREBP1c expression and function in steatosis. When hepatic lipid homeostasis is disrupted, FAs induce the expression of H19 RNA and PTBP1 and enhance their interaction. This facilitates PTBP1 protein interaction with Srebp1c mRNA and protein, further stimulating the lipogenic program.
Consequently, overexpression of H19 results in hepatic metabolic reprogramming and exacerbates dietinduced fatty liver. Our study provides a lncRNAmediated regulatory module to control steatosis.
Materials and Methods
Mouse models include maternal H19-deleted mice (Mat H19 -/-) with paternal H19-deleted mice (Pat H19 -/-) as wild-type controls, H19 overexpressed mice, and Ptbp1 knockdown mice. Basic procedures to analyze animal metabolic phenotypes and serum parameters, (19) RNA pull-down, and RNA immunoprecipitation have been described. (20) Primary hepatocyte isolation and culture, in vitro virus transduction and plasmid transfection, quantitative PCR, western blot, liver histology, hepatic lipid extraction, and blood chemistry, immunocytochemistry, and confocal imaging have been described. (21) (22) (23) (24) (25) Primer sequences are provided in Supporting Table S1 . Other potential H19 binding proteins from mass spectrometric analysis are provided in Supporting Table S2 . The coded human liver specimens were obtained through the Liver Tissue Cell Distribution System (Minneapolis, MN) (see Supporting Table S3 ). Because we did not ascertain individual identities associated with the samples, the Institutional Review Board for Human Research at the University of Connecticut determined that the project was not research involving human subjects.
Please see Supporting Information for detailed experimental models and conditions.
STATISTICAL ANALYSIS
Data are shown as the mean 6 standard error of the mean (SEM) and are representative of at least three independent experiments. Statistical analysis was carried out using the Student t test between two groups and one-way analysis of variance among multiple groups. P < 0.05 was considered statistically significant. The sample variation within each group was estimated to ensure that the variance was similar. All experiments were randomized by simple randomization based on a single sequence of random assignments.
SUPPORTING INFORMATION
The Supporting Information for this article includes three tables, 11 figures, and detailed experimental procedures.
Results

H19 INTERACTS WITH PTBP1 TO ENHANCE PTBP1-BINDING TO SREBP1 mRNA AND PROTEIN
lncRNAs often regulate target genes through interactions with RNA binding proteins. To understand the metabolic function of H19, the first step was to identify H19-interacting proteins. We cloned and synthesized biotin-labeled sense and antisense strands of full-length and 5 0 end of H19 RNA (Fig. 1A, left) . We conducted an RNA pull-down assay by incubating biotin-labeled full-length H19 sense or antisense (negative control) RNA with Hepa1 cell extracts. A band in the sense lane (red arrow) was excised, digested, and subjected to liquid chromatography-mass spectrometry to identify proteins that bound to the H19 RNA ( Fig. 1A , right; Supporting Fig. S2A ). The band likely contained multiple proteins of similar sizes. Indeed, a total of 48 candidates were identified (Supporting Table S2 ). From the 15 proteins that received the highest scores (Supporting Fig. S2A , bottom), six were selected for further validation based on the availability of antibodies. PTBP1 was the only protein validated as a binding partner of H19, and the interaction of PTBP1 with the 5 0 end of H19 was stronger than that of full-length H19, as demonstrated by RNA pull-down (Fig. 1B, left top) . In contrast, the sphingosine-1-phosphate lyase 1 antibody failed to detect sphingosine-1-phosphate lyase 1 binding to PTBP1, which was used as a negative control. The results of five other proteins are presented in Supporting Fig. S2B .
Because we are interested in the function of H19 in crosstalk with PTBP1 in lipid metabolism, we used online bioinformatics analysis tools (RBPmap, StarBase v2.0) to predict PTBP1 targets in lipid metabolic pathways. Srebp1c mRNA was predicted to contain multiple PTBP1 binding sites within its coding DNA sequence and 3 0 untranslated region (Supporting Fig.  S3A, B ). An RNA immunoprecipitation assay was carried out using an anti-PTBP1 antibody or mouse immunoglobulin G with Hepa1 cell lysates, which demonstrated that Srebp1c mRNA, but not farnesoid X receptor, fatty acid synthase (Fasn), peroxisome proliferator-activated receptor gamma (Pparc), or acetylcoenzyme A carboxylase mRNAs, was moderately enriched by PTBP1 versus control immunoglobulin G antibody (Supporting Fig. S3C ). However, we observed a significant interaction of PTBP1 with Srebp1c mRNA in the presence of H19 (Fig. 1B, left,  bottom) . Interestingly, coimmunoprecipitation (co-IP) and western blot also revealed a physical interaction between PTBP1 and SREBP1 proteins, and the interaction was enhanced by H19 ( Fig. 1B, right ; Supporting Fig. S3D ).
H19 INDUCES SREBP1 PROTEIN NUCLEAR TRANSLOCATION IN A PTBP1-DEPENDENT FASHION UNDER FASTING CONDITIONS
To better understand the regulation of SREBP1 protein by H19 and PTBP1, we overexpressed H19 and PTBP1 alone or in combination in Hepa1 cells and collected both cytosolic and nuclear proteins under either feeding or fasting (24 hours) conditions (Fig.  1C, upper) . H19 or PTBP1 slightly increased the endogenous nuclear SREBP1 (nSREBP1) protein under feeding conditions. Upon fasting, the induction of SREBP1 protein by H19 or PTBP1 was detectable to a much greater extent, which was further augmented by coexpression of both genes ( Fig. 1C, top ; Supporting Fig. S3E ). We also examined the effect of PTBP1 knockdown on SREBP1 expression (Fig. 1C, bottom) .
Short hairpin (sh) PTBP1 decreased nSREBP1 protein in both fed and fasted cells, and this effect was partially rescued by H19 in fasted cells. Furthermore, changes in subcellular localization of SREBP1 protein were evaluated under fasting conditions using confocal microscopy ( Fig. 1D) . In null cells (row 1), the SREBP1 protein was observed in cytoplasm and around the nuclear membrane. In H19 cells (row 2), more nSREBP1 proteins were detected in cells that expressed higher levels of PTBP1 protein (white versus purple). Knockdown of PTBP1 in the absence of H19 did not alter SREBP1 subcellular distribution (row 3), although it impeded SREBP1 nuclear translocation mediated by H19 (row 4). 
H19 AND PTBP1 INCREASE SREBP1 PROTEIN CLEAVAGE, STABILITY, AND TRANSCRIPTIONAL ACTIVITY
In Hepa1 and Huh7 cells treated with the transcriptional inhibitor actinomycin D to block RNA synthesis, overexpression of H19 and PTBP1 decreased Srebp1c mRNA degradation (Fig. 1E, left) . When Hepa1 cells were treated with cycloheximide (CHX) to inhibit protein synthesis, an increased SREBP1 protein stability by PTBP1 and H19 was observed (Fig.  1E, right) . Interestingly, H19 also increased PTBP1 protein half-life. We next treated primary hepatocytes with CHX to examine the effect of H19 on SREBP1 protein expression (Fig. 1F, left) . It was interesting to note that the basal precursor SREBP1 (pSREBP1) protein was decreased by H19 (p, green arrow versus blue arrow) concomitantly with increased nSREBP1 protein (n, purple arrow versus red arrow), suggesting increased protein cleavage. In addition, using a promoter reporter containing a sterol regulatory element response element, we observed enhanced SREBP1c transcriptional activity by overexpression of PTBP1 and H19 (Fig. 1F, right) .
H19 ENHANCES FA-INDUCED LIPID ACCUMULATION IN HEPATOCYTES
The important role of H19 in PTBP1-mediated SREBP1c expression prompted us to determine the impact of H19 RNA on neutral lipid accumulation in vitro in hepatocytes. Transient overexpression of H19 using adeno-associated virus 8 (AAV8)-H19 virus markedly augmented oleic acid (OA)-induced lipid accumulation in Hepa1 and Huh7 cells ( RNA pull-down with western blot to determine the specific interaction of sense H19 RNA with the PTBP1 protein but not with the sphingosine-1-phosphate lyase 1 protein (negative control). Left, bottom: RNA immunoprecipitation to determine the interaction between Srebp1c mRNA and PTBP1 protein using anti-PTBP1 or immunoglobulin G (negative control) in Hepa1 cells in the presence or absence of H19 RNA overexpression. Right: Co-IP followed by western blot to determine the effect of H19 on PTBP1 and SREBP1c protein interaction. Hepa1 cells were transduced with AAV-null or AAV-H19 for 24 hours, followed by transfection with Myc-PTBP1 or Flag-SREBP1c plasmid for 24 hours. Cells were then fasted in serum-free medium for 24 hours. Total proteins were collected for co-IP with the antiFlag antibody, and western blot analysis was performed with anti-Myc-tag or anti-Flag antibody. (C) Top: Western blot analysis to determine the effects of H19 and PTBP1 on nSREBP1 protein expression. Hepa1 cells were transduced with AAV8-null or AAV8-H19 virus for 24 hours and then transfected with Myc-PTBP1 for 24 hours. For fasting conditions, cells were treated for 24 hours with serum-free medium, followed by fractionation of cytoplasm and nucleus proteins. Anti-SREBP1, anti-PTBP1 and anti-Myc antibodies were used to detect SREBP1 and PTBP1 proteins, respectively. Bottom: Western blot analysis to determine the effect of knockdown of PTBP1 on nSREBP1 protein expression. Hepa1 cells were transduced with Lenti-Con or Lenti-shPTBP1 virus for 72 hours, followed by AAV8-null or AAV8-H19 for 72 hours. Anti-PTBP1 and anti-SREBP1 antibodies were used to detect nSREBP1 and PRBP1 proteins, respectively. (D) Confocal images of immunocytochemical analysis of SREBP1 and PTBP1 protein subcellular localization. Hepa1 cells were transduced with Lenti-pLKO or Lenti-shPTBP1 virus and selected with 1 mg puromycin for 7 days to generate stable cell lines. Cells were then transduced with AAV8-null or AAV8-H19 for 48 hours and fasted for 24 hours. SREBP1 and PTBP1 proteins were detected using respective antibodies. Pink arrow indicates cells with low PTBP1 expression; white arrow indicates cells with high PTBP1 expression. (E) Top: Hepa1 (left) and Huh7 (right) cells transfected with plasmid cytomegalovirus promoter DNA or H19 with or without PTBP1 were treated with actinomycin D (5 mg/mL). RNA was extracted at different time points (0, 30, 60 minutes), and Srebp1c mRNA was analyzed by quantitative PCR and normalized to b-actin. Data are shown as mean 6 SEM from triplicate assays. *P < 0.01 versus plasmid cytomegalovirus promoter DNA; # P < 0.001 versus H19 or PTBP1 alone. Bottom: Western blot analysis of protein expression in Hepa1 cells treated with CHX. H19 and PTBP1 were expressed alone or in combination using the same conditions as above. Red arrow indicates nSREBP1 increased in PTBP1 or H19 versus control. Blue arrow indicates PTBP1 increased in PTBP1 or H19 versus control. (F) Top: Western blot analysis of SREBP1 protein expression in primary hepatocytes treated with CHX. Primary hepatocytes were isolated from wild-type mice, cultured overnight, and transduced with AAV8-null or AAV8-H19 the next day for 24 hours. Cells were then fasted for 24 hours before treatment with CHX. Bottom: Transient transfection assay. The sterol regulatory element promoter luciferase reporter was transfected with SREBP1c expression plasmid in the presence or absence of PTBP1 or H19 coexpression in Hepa1 cells. Luciferase activity was normalized to bgal activity. *P < 0.01 versus lane 1; 0 ,6-diamidino-2-phenylindole; F, full-length; H1shP, AAV8-H19 1 shPTBP1; IB, immunoblot; IgG, immunoglobulin G; IP, immunoprecipitation; luc, luciferase; Nu, nucleus; pcDNA, plasmid cytomegalovirus promoter DNA; RIP, RNA immunoprecipitation; S, sense; SGPL1, sphingosine-1-phosphate lyase 1; shCon, shcontrol; shP, shPTBP1.
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Intriguingly, H19 RNA was highly induced by FAs, including OA, palmitic acid, butyric acid, and stearic acid ( Fig. 2B, right; Supporting Fig. S4A ). In addition, H19 enhanced lipid staining in Hepa1 and Huh7 cells treated with palmitic acid and stearic acid (Supporting Fig. S4B ). The results suggest that H19 may function as an FA sensor to modulate lipogenesis. It was noted that transient expression of H19 RNA alone had less effect on cellular lipid levels ( Fig. 2A,B Supporting Fig. S4C ). The SREBP1c target gene FASN, which is a critical enzyme to catalyze FA synthesis, was not correspondingly induced by H19 alone; however, its expression was stimulated by OA and further enhanced by H19 in OA-treated cells. Thus, the modest impact of H19 on lipid accumulation could be attributed to the delayed activation of FASN. Similar to H19, transient overexpression of PTBP1 promoted OA-mediated lipid synthesis and enhanced the lipogenic effect of H19 (Fig. 2D) , which could be attributed to the enhanced binding of H19 to PTBP1 by OA treatment (Supporting Fig. S4D ). Knockdown of PTBP1 or SREBP1 significantly diminished H19-induced lipid accumulation (Fig. 2E left) , and knockdown of SREBP1 also impeded PTBP1-induced lipid accumulation (Fig. 2E right) . Interestingly, shSREBP1 also diminished PTBP1 protein (Fig. 2F) , suggesting a potential feedforward regulation of PTBP1 expression by SREBP1. Therefore, the interaction of PTBP1 and H19 facilitates SREBP1c-mediated de novo lipogenesis.
PROLONGED H19 EXPRESSION FACILITATES THE DEVELOPMENT OF HEPATIC STEATOSIS
We next investigated the in vivo effect of H19 using two experimental approaches: first, overexpressing H19 alone for a prolonged period of time (Fig. 3) and, second, overexpressing H19 for a short time in the presence of a high-fat/high-sucrose (HFHS) diet (Fig. 4) .
We overexpressed H19 in mouse liver through tail vein injection of AAV8-H19 (thereafter referred to as "H19 mice") or AAV8-null (scramble control, "null mice") driven by a specific promoter thyroxine-binding globulin for hepatic-directed delivery. H19 expression for 5 months resulted in global changes in hepatic gene expression in glucose and lipid metabolism (Fig. 3A) . Several signaling pathways were activated, including extracellular signal-regulated kinase, (26) phosphoinositol 3-kinase AKT/protein kinase B, (27) and c-Jun N-terminal kinase. (28) Specifically, the levels of phosphorylated extracellular signal-regulated kinase, phosphorylated AKT, and phosphorylated c-Jun N-terminal kinase were induced to various extents in H19 mouse livers (Fig. 3B, top) . In addition, H19 mice exhibited elevated fasting glucose levels and insulin levels (Fig. 3B, bottom) , suggesting a dysfunction in response to fasting as a result of insulin resistance. The results were in agreement with the report that mice with activation of extracellular signal-regulated kinase in the livers showed fasting hyperglycemia. (26) Despite these noticeable metabolic alterations, hepatic and serum TG levels remained unaltered (not shown).
Hepatic H19 expression remained constantly expressed (15-fold) in mice 10 months after AAV8-H19 transduction (Fig. 3C left) . The H19 liver appeared pale in color compared to the null liver (middle), which was associated with significantly increased liver weight (right) and TG content (Fig. 3D) . Interestingly, serum TG levels did not differ between H19 and null mice. Severe steatosis (both macrovesicular and microvesicular) was visualized by hematoxylin and eosin and oil red O staining in H19 mice (Fig. 3E) . Glycogen content was moderately increased in H19 mice compared to null mice (periodic acid-Schiff [PAS] staining), and no hepatic fibrosis was observed in H19 or null mice (trichrome Masson staining). We next analyzed representative genes in pathways coordinating lipid homeostasis, including lipid uptake, oxidation, and synthesis. (19) The mRNA expression of Pparc and its target Cd36 was elevated, while Ppara and its target Cpt1 were down-regulated (Fig. 3F,  left) , suggesting increased lipid uptake and decreased oxidation. Consistently, the nuclear protein expression of SREBP1, a key de novo lipogenic transcription factor, and its targets PPARc and FASN, as well as PTBP1 and acetyl-coenzyme A carboxylase proteins, were coordinately elevated, whereas PPARa protein was down-regulated (Fig. 3F, right) .
Srebp1c mRNA showed no significant changes in H19 versus null liver, whereas the elevated nSREBP1 protein was correlated with the decreased pSREBP1 protein, suggesting increased cleavage. On the other hand, the expression of key genes in very low-density lipoprotein secretion (Mtp, Apob) did not change in H19 versus null liver (Supporting Fig. S5A ), which was consistent with the unaltered serum TG levels (Fig. 3D, right) . We also analyzed the expression of genes in lipoprotein metabolism (Supporting Fig.  S5B ) and observed unique change patterns. Because the body weight of H19 and null mice was similar (Supporting Fig. S5C ), the global changes in hepatic metabolic genes were likely due to a direct effect of H19 in the liver. Consistent with the severe steatosis, increased insulin resistance and glucose intolerance developed in H19 versus null mice (Supporting Fig. S5D ). 
OVEREXPRESSION OF H19 EXAGGERATES HFHS-INDUCED STEATOSIS
Although it took more than 5 months for H19 to spontaneously induce fatty liver, based on the results that H19 enhanced FA-induced lipid accumulation in hepatocytes (Fig. 2) , we hypothesized that H19 may facilitate the development of steatosis induced by an HFHS diet. (29) We transduced mice with AAV8-H19 or null control for 1 week, followed by HFHS feeding for 5 weeks. H19 RNA, nSREBP1, and PTBP1 proteins were markedly induced in mice fed the HFHS diet compared to the chow diet (Fig. 4A) . As predicted, overexpression of H19 exaggerated hepatic steatosis by the HFHS diet, as indicated by the increased neutral lipid staining and elevated liver TG levels (Fig. 4B) . Importantly, nSREBP1 protein levels were strongly elevated in H19 mice, which was accompanied by the induction of PTBP1 protein, decreased PPARa, and increased PPARc proteins (Fig. 4C) . No significant changes in body weight, white fat, brown fat, and serum TG levels were observed between null-HFHS and H19-HFHS mice (Supporting Fig. S6A ). No significant differences in PAS staining and trichrome Masson staining were observed between the two groups (Supporting Fig. S6B ). Quantitative PCR revealed common as well as differential gene expression profiles in null-HFHS and H19-HFHS mice (Supporting Fig. S6C ) compared with null and H19 mice (Supporting Fig. S5A-C) , suggesting an influence of the HFHS diet on H19-mediated steatosis. Overall, the results showed that H19 exacerbated the hepatic lipid phenotype induced by an HFHS diet.
DEFICIENCY IN H19 AND PTBP1 PREVENTS HFHS-INDUCED STEATOSIS
To further establish the endogenous effect of H19 in lipogenesis, Mat H19 -/-and its wild-type control Pat H19 -/-(Supporting Fig. S6D ) were challenged with the HFHS diet for 2 months, a feeding period chosen to ensure that steatosis was well developed in Pat H19 -/-mice. Lipid droplets became evident in Pat H19 -/-mice but were largely prevented from developing in Mat H19 -/-mice (Fig. 4D ). In agreement with this observation, hepatic TG content as well as the levels of nSREBP1, PTBP1, and FASN proteins were concurrently lower in Mat H19 -/-versus Pat H19 -/-mice. pSREBP1 protein, on the other hand, was higher in Mat H19 -/-versus Pat H19 -/-mice, suggesting that the diminished nSREBP1 was due to decreased cleavage.
We next determined the effect of PTBP1 knockdown in HFHS-induced steatosis. We used lentishPTBP1 virus to transduce wild-type mice for 1 week, followed by HFHS feeding for 2 months. PTBP1 knockdown markedly diminished hepatic lipid accumulation and TG content, which was accompanied by the down-regulation of pSREBP1, nSREBP1, FASN, PTBP1, and PPARc proteins and increased PPARa protein compared to control mice (Fig. 4E) .
We further conducted rescue experiments by knockdown of PTBP1 in H19 mice. We observed markedly diminished steatosis in H19-shPTBP1 compared with H19 mice (Fig. 4F) . pSREBP1, nSREBP1, PTBP1, and FASN proteins were coordinately decreased. shPTBP1 did not alter glycogen storage (PAS staining) (Supporting Fig. S7A ) or H19 RNA levels (Supporting Fig. S7B ) compared with the control. It was interesting to note that Srebp1c mRNA was not altered by shPTBP1 in control or H19 mice but was increased in Mat H19 -/-versus Pat H19 -/-mice (Supporting Fig. S7C ). We speculate that H19 functions as a guide RNA scaffold to recruit PTBP1 to Srebp1c mRNA and that loss of H19 likely causes Srebp1c release, resulting in increased levels. Taken together, the results suggest that H19 induces fatty liver through a PTBP1-dependent mechanism.
H19 INCREASES NUCLEAR LOCALIZATION OF SREBP1 PROTEIN IN RESPONSE TO FASTING
We examined hepatic SREBP1 and PTBP1 proteins in cytoplasm and nucleus isolated from null or H19 mice fed the HFHS diet for 5 weeks under feeding and fasting conditions (Fig. 5A ). In agreement with the decreased Srebp1c mRNA upon fasting (Supporting Fig. S7D ), the nuclear SREBP1 protein was also reduced by fasting versus feeding in null (-) mice (blue arrow versus green arrow). In H19 (1) mice, nSREBP1 protein was highly up-regulated under feeding conditions, which was further elevated by fasting (purple arrow versus red arrow). Under feeding conditions, PTBP1 protein was mostly observed in the nuclear fractions compared to the cytosolic fractions. Upon fasting, the levels of PTBP1 proteins were decreased in the cytoplasm but slightly increased in the nucleus, suggesting an increased nuclear translocation.
The in vivo SREBP1 and PTBP1 protein interaction in the nucleus and the cytoplasm of mouse liver was assessed. Co-IP assays revealed a stronger interaction in chow-H19 versus chow-null liver (Fig. 5B,  left) , and the interaction was enhanced by the HFHS diet. A weaker interaction but with a similar pattern was observed in the cytoplasm (Fig. 5B, right) . The interaction, however, was largely diminished in H19 -/-mice (Fig. 5C) . RNA immunoprecipitation revealed a significant enrichment of PTBP1 protein to Srebp1c mRNA in null liver, which was further augmented in H19 liver (Fig. 5D, left) . In addition, the association of H19 RNA with endogenous PTBP1 protein in mouse liver was markedly enhanced by the HFHS diet (Fig. 5D, right) . Hepatic H19 RNA was maintained at constant high levels 1 year after H19 overexpression (Supporting Fig. S7E ). In contrast, H19 RNA expression in muscle and adipose tissues did not alter in H19 versus control mice (Supporting Fig. S7F) .
Importantly, the expression of PTBP1 mRNA and protein, as well as H19 RNA, was highly induced in human NASH cirrhotic livers versus normal livers (Fig. 5E) . We also analyzed H19 RNA and PTBP1 FIG. 5. H19 promotes PTBP1 subcellular translocation and PTBP1/SREBP1c interaction. (A) Western blot analysis of cytoplasmic and nuclear proteins isolated from null and H19 mouse livers fed the HFHS diet under feeding and fasting conditions. Loading controls: tubulin (cytoplasmic) and lamin A/C (nuclear) proteins. (B,C) Co-IP followed by western blot to determine the in vivo endogenous PTBP1 and SREBP1c protein interaction. Nuclear and cytoplasmic extracts were isolated from mouse livers of null and H19 mice fed a chow or HFHS diet (B) or paternal H19 -/-(wild-type control) and maternal H19 -/-mice fed the HFHS diet (C). Co-IP was performed using SREBP1 antibody, and western blot analysis was performed using PTBP1 and SREBP1 antibodies. Input, the same amount of protein from each group was loaded. (D) Left: RNA immunoprecipitation to determine the in vivo interaction between Srebp1c mRNA and PTBP1 protein using anti-PTBP1 or immunoglobulin G (negative control) in livers of null (lanes 1, 2) or H19 (lanes 3, 4) mice. Right: RNA immunoprecipitation to detect the association of H19 RNA with endogenous PTBP1 protein in mouse livers from null or H19 mice fed the chow or HFHS diet. Data are shown as mean 6 SEM. *P < 0.05 red versus black; # P < 0.05 pink versus green. (E) Top: Quantitative PCR of PTBP1 mRNA and H19 RNA in human normal livers (n 5 6) and NASH cirrhotic livers (n 5 17). Each dot represents an individual sample. Data are shown as mean 6 SEM. *P < 0.05 versus normal. Bottom: Western blot analysis of PTBP1 protein in human normal livers (n 5 3) and NASH cirrhotic livers (n 5 8). Each line represents an individual sample. (F) Left and middle: Quantitative PCR of H19 RNA and PTBP1 mRNA in human normal livers (n 5 10), NASH-No-Fat livers (male, n 5 9; female, n 5 7), and NASH-Fat livers (male, n 5 6; female, n 5 15). Each dot represents an individual sample. Data are shown as mean 6 SEM. *P < 0.05 versus normal. Right: Western blot analysis of PTBP1 protein in human normal livers (n 5 6), NASH-Fat livers (male, n 5 6; female, n 5 15). Samples were analyzed in two gels. Each line represents an individual sample. **P < 0.01 versus normal. See also Supporting Fig. S7D . Abbreviations: cir, cirrhosis; Cyto, cytoplasm; IgG, immunoglobulin G; IP, immunoprecipitation; Nu, nucleus; RIP, RNA immunoprecipitation.
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expression in human NASH-No-Fat and NASH-Fat livers from both male and female patients to determine gender difference. H19 RNA was similarly elevated in male and female NASH-No-Fat specimens (Fig. 5F , left). It was more highly induced in NASH-Fat female versus NASH-Fat male patients, which did not reach statistical significance between the two groups. To our surprise, PTBP1 mRNA was not induced in NASHNo-Fat and NASH-Fat livers versus normal livers (Fig. 5F, middle) . Nonetheless, PTBP1 protein was strikingly elevated in both male and female NASH patients (Fig. 5F, right) . Taken together, these results demonstrate the clinical significance of both genes in regulating the development of human chronic liver diseases.
H19 DISRUPTS METABOLOMICS PROFILING IN RESPONSE TO FASTING
Metabolomics serves as a powerful approach to identify different molecules produced in cells and offers new insight into the cellular metabolic pathways regulated by H19. Untargeted metabolomics profiling (gas chromatography time-of-flight mass spectrometry) was used to elucidate changes in liver metabolites in null and H19 overexpressing mice by 10 months under both fasting and feeding conditions. The data sets were subjected to nonsupervised multivariate data analysis to evaluate the presence of a metabolomic pattern that could discriminate between null and H19 mice subjected to fasting.
Correlation matrix and cluster analysis revealed both positively and negatively correlated metabolites (Supporting Fig. S8A ). The differential abundance of metabolites in response to fasting versus feeding in null and H19 mice was further visualized by a heatmap (Supporting Fig. S8B; Fig. 6A ). It was noted that the levels of the majority of metabolites were either increased or decreased in response to fasting in null mice versus null-feed, and such responses were blunted to a large extent in H19 mice. The principal component analysis (Supporting Fig. S8C ) and partial least squares discriminant analysis (Fig. 6B ) score plots showed an almost complete separation between nullfast with null-feed and those overexpressed with H19. Due to the lost response to fasting, metabolites altered in H19-fast versus null-fast were largely enriched in glucose metabolic pathways, including glycolysis and gluconeogenesis ( Fig. 6C; Supporting Fig. S9A ). In contrast, other metabolites including FAs and amino acids remained at low levels in H19-fast versus nullfast mice, whereas cholesterol levels remained unchanged in H19 versus null mice (Supporting Fig.  S9B-F) . Among all the metabolites, glucose-1-phosphate and glucose-6-phosphate were most highly enriched in H19-fast versus null-fast mice, as shown in the volcano plot (Fig. 6D) , whereas the concentrations of N-methylalanine and methionine were markedly reduced (Fig. 6E) . Overall, the results suggest that hepatic overexpression of H19 has a substantial impact on the stress-response capacity of liver, which results in a wide-ranging disruption of metabolic pathways.
OVEREXPRESSION OF H19 REPROGRAMS HEPATIC LIPID SPECIES
Lipidomics analysis provides an unbiased approach to further define the altered hepatic lipid species by H19. In general, a majority of individual TG lipid species were found to be highly up-regulated in H19 mice compared with null mice under feeding conditions and were further elevated by fasting ( Fig. 7A-C ; Supporting Fig. S10A-C) . In contrast, there were no differences in levels of absolute and relative TG abundance between fasting and feeding conditions in null mice. Among other lipid species, diacylglycerols (34:1), (36:2), (38:3), and (38:5) and cholesterol ester (22:6) exhibited similar changes to TG species (Supporting Fig. S11A,B) . Interestingly, several phosphatidyl choline species, including (38:4) A and (38:5) A, were only elevated in H19-Fast mice (Supporting Fig.  S11C ). On the contrary, FA (18:2), FA (18:3), FA (20:4), and FA (22:6) were induced by fasting in null but not in H19 mice (Supporting Fig. S11D ). In addition, ceramide species 38:1 were similarly elevated in H19-Feed and H19-Fast mice (Supporting Fig.  S11E ).
Discussion
H19 has been documented as a tumor suppressor or oncogene in various tissues or cells, (12, 13, 30) but its function in the liver remains to be defined. In this study, we report a role of H19 in modulating hepatic lipid metabolism. The key findings include the following: (1) H19 acts as an interacting partner of PTBP1, and their association is enhanced by nutrient status (FA and HFHS diet); (2) H19 facilitates PTBP1 binding to Srebp1c mRNA in cytoplasm, resulting in increased stability; (3) H19 promotes PTBP1 binding to SREBP1 protein in the nucleus, which in turn augments Srebp1c transcriptional activity; (4) H19 induces pSREBP1 protein cleavage and nSREBP1 nuclear translocation in a PTBP1-dependent fashion; (5) expression of H19 and PTBP1 is up-regulated by the HFHS diet, which further elevates SREBP1 and stimulates the PTBP1 and SREBP1 interaction; and (6) H19 reprograms hepatic fasting metabolic response into a "pseudo-fed" state by inducing nuclear accumulation of SREBP1 protein, which exacerbates HFHS-induced fatty liver. Both H19 and PTBP1 are markedly induced in human cirrhotic livers, demonstrating their clinical significance in the regulation of chronic liver diseases.
Several lncRNAs have been reported to be associated with PTBP1. Pnky and TUNA can recruit PTBP1 to regulate neuronal differentiation of neural stem cells (31) and embryonic stem cells. (32) MEG3 binds to PTBP1 to control small heterodimer partner mRNA stability and cholestatic liver injury. (20) Algorithms to predict mRNA targets of PTBP1 across the genome using genomic sequences have not been developed yet; therefore, the prediction of PTBP1-targeted mRNAs is limited to specific genes of interest. In this study, we focused on genes in lipid metabolic pathways and identified Srebp1c as a downstream gene regulated by PTBP1.
Based on the results obtained from in vitro and in vivo models in this study, PTBP1-mediated elevation of SREBP1 protein likely results from increased stability because knockdown of PTBP1 decreases both pSREBP1 and nSREBP1 in null and H19-overexpresed mice. On the other hand, H19 increases SREBP1 at least in part by inducing SREBP1 protein cleavage, as evidenced by decreased pSREBP1 and increased nSREBP1 in H19 mice but increased pSREBP1 and decreased nSREBP1 in H19 -/-mice. Mass spectrometric analysis did not identify SREBP1 as a potential H19 interacting partner; therefore, H19 may regulate SREBP1 cleavage through an unknown intermediate protein. Interestingly, PTBP1 is essential for H19-induced SREBP1 nuclear translocation under fasting conditions. Additional evidence supporting PTBP1-dependent regulation of SREBP1 expression by H19 includes the following: (1) overexpression of H19 increases both SREBP1 and PTBP1 protein, (2) H19 deficiency decreases both SREBP1 and PTBP1 protein, (3) knockdown of PTBP1 decreases SREBP1 without altering H19 levels, and (4) knockdown of PTBP1 in H19 overexpressed mice decreases SREBP1.
It is noted that Srebp1c mRNA is not markedly elevated in H19 mice, suggesting that H19 does not likely regulate Srebp1c gene transcription. However, overexpression of H19 and PTBP1 in vitro in cell models increases Srebp1c mRNA stability. Because PTBP1 is mostly expressed in the nucleus, its effect in cytoplasm may be moderate in vivo in mouse liver. The effect of PTBP1 could also be masked by other transcription factors and signaling events controlling Srebp1c expression.
In addition to the changed metabolic and lipogenic program, other pathways are also altered in H19 mice, including lipid uptake and oxidation and lipoprotein metabolism. Interestingly, H19 pushes the liver into a "fed"-like state, as supported by hyperglycemia and hyperinsulinemia, increased nuclear SREBP1c protein despite decreased Srebp1c mRNA in the fasted state, and activation of the insulin-signaling pathway in liver. Overall, a global change of lipid metabolic homeostasis by H19 facilitated the development of fatty liver.
New lncRNAs associated with human liver diseases are constantly identified. (33) Recent studies have demonstrated that H19 RNA was elevated in human liver fibrosis and cirrhosis, (14) as well as in human primary sclerosing cholangitis and primary biliary cirrhosis patients. (34) The present study provides further evidence for the induction of H19 and PTBP1 in human NASH fatty liver. These results may have important clinical implications, suggesting that reducing the expression or blocking the function of H19 and PTBP1 could provide novel treatment strategies for chronic liver diseases.
In summary, the interplay between H19 RNA and PTBP1 protein functions as an essential component of the hepatic metabolic network (Fig. 8) . Intriguingly, FAs stimulate H19 and PTBP1 expression, which in turn augments the lipogenic effect of FAs by enhancing SREBP1c expression and transactivation, forming a robust feedforward regulatory loop. The importance of such a mechanism becomes more prominent under stress or disease conditions. In addition to modulating lipid homeostasis, up-regulation of H19 exerts a major influence on glucose metabolism. Because glucose homeostasis and lipid metabolism are closely intertwined, future work will continue to identify additional targets regulated by the H19/PTBP1 circuit in glucose metabolic pathways that are associated with the development of liver metabolic disorders.
FIG.
8. An H19/PTBP1 feedforward metabolic circuit to reprogram hepatic response to fasting by modulating SREBP1c expression. H19 functions as a lipid sensor, and its expression is induced by FAs and the HFHS diet, which in turn enhances H19 association with the PTBP1 protein. The interaction of H19 RNA and PTBP1 protein results in dual effects: it facilitates PTBP1 binding to Srebp1c mRNA in the cytoplasm, leading to increased Srebp1c mRNA stability, and it stimulates PTBP1 binding to SREBP1c protein in the nucleus, augmenting SREBP1c transcriptional activity. In addition, H19 induces pSREBP1c protein cleavage; it also promotes nSREBP1c nuclear translocation in PTBP1-dependent fashion under fasting conditions. Therefore, H19 reprograms the hepatic response to fasting and pushes the liver into a "fed"-like state. The H19/PTBP1/ SREBP1 metabolic circuit generates a feedforward amplifying signal to exacerbate the development of fatty liver by the HFHS diet. Abbreviations: ER, endoplasmic reticulum; FFA, free FA; SRE, sterol regulatory element.
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